{"doi":"10.1200/jco.2005.23.16_suppl.736","title":"A phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer","abstract":null,"journal":"Journal of Clinical Oncology","year":2005,"id":612288,"datarank":0.492694283033385,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.2847501288654014,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.2847501288654014,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":3,"citers_with_citation_signal":3,"citers_with_endowment":3,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1576443,"name":"R. Tanasescu","orcid":null,"position":1,"is_corresponding":false},{"id":1576444,"name":"C. Vasiliniuc","orcid":null,"position":2,"is_corresponding":false},{"id":1576445,"name":"L. Neamtiu","orcid":null,"position":3,"is_corresponding":false},{"id":1576446,"name":"N. Ghilezan","orcid":null,"position":4,"is_corresponding":false},{"id":1576442,"name":"D. Grecea","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer","abstract":"736 Background: A phase II study was conducted to evaluate the efficacy and tolerability of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Methods: 60 patients with metastatic breast cancer received either docetaxel 35mg/m2 weekly for a median 10 (8–12) consecutive weeks (n=25), or docetaxel 100mg/m2 on day 1 every 3 weeks, 6 cycles (n=35). The median age of patients was 46 years(31–66) with 22(36,6%) premenopausal and 38 (63,4%) postmenopausal. 50 patients (83,3%) received docetaxel as first line treatment for metastatic breast cancer, and the other 10 patients (16,6%) received it as second line treatment. Results: The incidence of all grade 3–4 adverse events was higher in the 3-weekly group than in the weekly group (64 versus 30) and the number of patients with grade 3–4 adverse events was also grater in the 3-weekly group (23 versus 12). Intent to treat overall response rate was 42% and 36% in the 3 weekly and weekly group, respectively. Median time to progression was 5.8 and 5.2 months after 3-weekly and weekly docetaxel, respectively. Conclusions: Weekly docetaxel is an active regimen in metastatic breast cancer with comparable efficacy to 3-weekly docetaxel. Both schedules were well tolerated, weekly docetaxel appears to have a more favourable toxicity profile, providing an attractive strategy for palliative treatment of metastatic breast cancer. No significant financial relationships to disclose.","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23304386","pmcid":null,"openalex_id":"https://openalex.org/W2565070599","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.736","host_type":"publisher"},{"url":"https://doi.org/10.1200/jco.2005.23.16_suppl.736","host_type":"journal"}],"fields_of_study":["Cancer Treatment and Pharmacology","Colorectal Cancer Treatments and Studies","Advanced Breast Cancer Therapies"],"mesh_terms":[],"keywords":["Docetaxel","Medicine","Metastatic breast cancer","Tolerability","Internal medicine","Breast cancer","Regimen","Adverse effect","Oncology","Cancer","Chemotherapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T02:43:27.378803Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}